Q-omics provides the consensus-scored DSTNP5 profile across patient tissues and cancer cell-line models. DSTNP5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, DSTNP5 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, DSTNP5 RNA expression shows 6,030 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and BRCA as cancer lineages where DSTNP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSTNP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSTNP5 survival associations across molecular data types. DSTNP5 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSTNP5 RNA expression–survival associations across cancer types. High DSTNP5 expression shows unfavorable associations in STAD, OV, UVM, BRCA, READ and ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for DSTNP5 RNA expression.
This table summarizes DSTNP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DSTNP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSTNP5 shows lower tumor expression in COAD, STAD and THCA and higher tumor expression in BRCA, LUAD and LIHC. The BRCA box plot shows higher DSTNP5 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with DSTNP5 in patient tissues and cancer cell lines. In patient samples, DSTNP5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
